LMDXF — LumiraDx Share News
0.000.00%
Last trade - 00:00- $1.64m
- $378.94m
- $254.48m
Brief: Lumiradx Announces Commercial Shipment Of Its Point Of Care Nt-Probnp Test In Europe
Brief: Lumiradx Announces Receipt Of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency
Brief: Lumiradx Latest Cost Reduction Program Continues Progress Toward Operating Cash Flow Breakeven By The End Of 2023
Brief: Lumiradx Says Received $14.2 Mln In Grants From Bill&Melinda Gates Foundation For Ongoing Development Of Point Of Care Molecular Tuberculosis Testing System
Brief: Lumiradx Continues Commercial Expansion Of Its Rapid Microfluidic Immunoassay HbA1c Test
Brief: Lumiradx Reports Third Quarter 2022 Results
U.S. STOCKS ON THE MOVE-Cisco, Babcock & Wilcox, Snap, Getty Images
U.S. STOCKS ON THE MOVE-Canadian Solar, Applied Materials, Gold and copper miners
LumiraDx falls on weak Q2 results
Brief: LumiraDx Ltd Reports Q2 Loss Per Share Of $0.58
Brief: Bill & Melinda Gates Foundation Reports 15.8% Stake In Lumiradx Ltd As Of July 25, 2022 - SEC Filing
LumiraDx tumbles on $100 mln equity raise
Brief: LumiraDx Announces Pricing Of Public Offering Of Common Shares And Concurrent Private Placement
Brief: LumiraDx Announces Proposed Public Offering Of Common Shares
Brief: LumiraDx Files For Offering 40 Million Of Common Shares
Europe Research Roundup: Air France-KLM, Epiroc AB, Heineken NV
Brief: LumiraDx Achieves CE Mark For Covid-19 Antigen Test On Amira, Its New Low-Cost Testing System
U.S. STOCKS ON THE MOVE-Grab Holdings Ltd, HeartCore Enterprises Inc, Twitter Inc
U.S. STOCKS ON THE MOVE-Omniq Corp, LumiraDx Ltd, Caterpillar Inc